Literature DB >> 9566919

AP-1 factors play an important role in transformation induced by the v-rel oncogene.

J Kralova1, A S Liss, W Bargmann, H R Bose.   

Abstract

v-rel is the oncogenic member of the Rel/NF-kappaB family of transcription factors. The mechanism by which v-Rel induces transformation of avian lymphoid cells and fibroblasts is not precisely known. However, most models propose that v-rel disrupts the normal transcriptional regulatory network. In this study we evaluated the role of AP-1 family members in v-Rel-mediated transformation. The overexpression of v-Rel, c-Rel, and c-Rel delta resulted in a prolonged elevation of c-fos and c-jun expression and in a sustained repression of fra-2 at both the mRNA and protein levels in fibroblasts and lymphoid cells. Moreover, the transforming abilities of these Rel proteins correlated with their ability to alter the expression of these AP-1 factors. v-Rel exhibited the most pronounced effect, whereas c-Rel, with poor transforming ability, elicited only moderate changes in AP-1 levels. Furthermore, c-Rel delta, which exhibits enhanced transforming potential relative to c-Rel, induced intermediate changes in AP-1 expression. To directly evaluate the role of AP-1 family members in the v-Rel transformation process, a supjun-1 transdominant mutant was used. The supjun-1 mutant functions as a general inhibitor of AP-1 activity by inhibiting AP-1-mediated transactivation and by reducing AP-1 DNA-binding activity. Coinfection or sequential infection of fibroblasts or lymphoid cells with viruses carrying rel oncogenes and supjun-1 resulted in a reduction of the transformation efficiency of the Rel proteins. The expression of supjun-1 inhibited the ability of v-Rel transformed lymphoid cells and fibroblasts to form colonies in soft agar by over 70%. Furthermore, the expression of supjun-1 strongly interfered with the ability of v-Rel to morphologically transform avian fibroblasts. This is the first report showing that v-Rel might execute its oncogenic potential through modulating the activity of early response genes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9566919      PMCID: PMC110679          DOI: 10.1128/MCB.18.5.2997

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  80 in total

1.  Cloning of the p50 DNA binding subunit of NF-kappa B: homology to rel and dorsal.

Authors:  S Ghosh; A M Gifford; L R Riviere; P Tempst; G P Nolan; D Baltimore
Journal:  Cell       Date:  1990-09-07       Impact factor: 41.582

2.  The DNA binding subunit of NF-kappa B is identical to factor KBF1 and homologous to the rel oncogene product.

Authors:  M Kieran; V Blank; F Logeat; J Vandekerckhove; F Lottspeich; O Le Bail; M B Urban; P Kourilsky; P A Baeuerle; A Israël
Journal:  Cell       Date:  1990-09-07       Impact factor: 41.582

Review 3.  Nuclear targets for transcription regulation by oncogenes.

Authors:  A Gutman; B Wasylyk
Journal:  Trends Genet       Date:  1991-02       Impact factor: 11.639

4.  c-rel activates but v-rel suppresses transcription from kappa B sites.

Authors:  J Inoue; L D Kerr; L J Ransone; E Bengal; T Hunter; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

5.  Interaction of the v-rel protein with an NF-kappa B DNA binding site.

Authors:  N Kabrun; J W Hodgson; M Doemer; G Mak; B R Franza; P J Enrietto
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-01       Impact factor: 11.205

6.  vRel is an inactive member of the Rel family of transcriptional activating proteins.

Authors:  P M Richardson; T D Gilmore
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

7.  The v-rel oncogene encodes a kappa B enhancer binding protein that inhibits NF-kappa B function.

Authors:  D W Ballard; W H Walker; S Doerre; P Sista; J A Molitor; E P Dixon; N J Peffer; M Hannink; W C Greene
Journal:  Cell       Date:  1990-11-16       Impact factor: 41.582

8.  The v-rel oncogene of avian reticuloendotheliosis virus transforms immature and mature lymphoid cells of the B cell lineage in vitro.

Authors:  J Y Zhang; W Olson; D Ewert; W Bargmann; H R Bose
Journal:  Virology       Date:  1991-08       Impact factor: 3.616

9.  Overexpression of avian or mouse c-jun in primary chick embryo fibroblasts confers a partially transformed phenotype.

Authors:  M Castellazzi; J P Dangy; F Mechta; S Hirai; M Yaniv; J Samarut; A Lassailly; G Brun
Journal:  Oncogene       Date:  1990-10       Impact factor: 9.867

10.  Expression of different Jun and Fos proteins during the G0-to-G1 transition in mouse fibroblasts: in vitro and in vivo associations.

Authors:  K Kovary; R Bravo
Journal:  Mol Cell Biol       Date:  1991-05       Impact factor: 4.272

View more
  16 in total

1.  A novel interferon regulatory factor (IRF), IRF-10, has a unique role in immune defense and is induced by the v-Rel oncoprotein.

Authors:  Jirí Nehyba; Radmila Hrdlicková; Joan Burnside; Henry R Bose
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

2.  Mutational analysis of the v-Rel dimerization interface reveals a critical role for v-Rel homodimers in transformation.

Authors:  Andrew S Liss; Henry R Bose
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

3.  Mutations in the v-Rel transactivation domain indicate altered phosphorylation and identify a subset of NF-kappaB-regulated cell death inhibitors important for v-Rel transforming activity.

Authors:  Béatrice Rayet; Yongjun Fan; Céline Gélinas
Journal:  Mol Cell Biol       Date:  2003-03       Impact factor: 4.272

4.  CAPERalpha is a novel Rel-TAD-interacting factor that inhibits lymphocyte transformation by the potent Rel/NF-kappaB oncoprotein v-Rel.

Authors:  Jui Dutta; Gaofeng Fan; Céline Gélinas
Journal:  J Virol       Date:  2008-08-27       Impact factor: 5.103

5.  Characterization of ATF2 in Rel/NFκB oncogenesis reveals its role in the regulation of Ras signaling.

Authors:  Andrew S Liss; Henry R Bose
Journal:  Small GTPases       Date:  2011-03

6.  Differential regulation of the inhibitor of apoptosis ch-IAP1 by v-rel and the proto-oncogene c-rel.

Authors:  Jarmila Kralova; Andrew S Liss; William Bargmann; Cullen Pendleton; Janani Varadarajan; Emin Ulug; Henry R Bose
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

7.  Dominant negative c-jun inhibits activation of the cyclin D1 and cyclin E kinase complexes.

Authors:  R F Hennigan; P J Stambrook
Journal:  Mol Biol Cell       Date:  2001-08       Impact factor: 4.138

8.  Interferon regulatory factor 4 contributes to transformation of v-Rel-expressing fibroblasts.

Authors:  R Hrdlicková; J Nehyba; H R Bose
Journal:  Mol Cell Biol       Date:  2001-10       Impact factor: 4.272

9.  Mapping of a serine-rich domain essential for the transcriptional, antiapoptotic, and transforming activities of the v-Rel oncoprotein.

Authors:  C Chen; F Agnès; C Gélinas
Journal:  Mol Cell Biol       Date:  1999-01       Impact factor: 4.272

10.  Reticuloendotheliosis virus strain T induces miR-155, which targets JARID2 and promotes cell survival.

Authors:  Mohan T Bolisetty; George Dy; Wayne Tam; Karen L Beemon
Journal:  J Virol       Date:  2009-09-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.